Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

November 21, 2006 09:02 ET

Holmes Biopharma-Grand Opening Held for Omaha Facility

SCOTTSDALE, ARIZONA--(CCNMatthews - Nov. 21, 2006) - Holmes Biopharma, Inc. (OTCBB:HLMB) and its clinical research subsidiary, Qualia Clinical Research Service Inc ("Qualia") hosted the grand opening of their research facility located in Omaha Nebraska. The well-attended event included speeches by the Mayor of Omaha, President of the Omaha Chamber of Commerce and management from both Holmes and Qualia.

The new 23,000 square foot clinical research facility is designed for Phase 1 trials of drugs that will tackle many conditions and diseases such as hypertension, Alzheimer's, rheumatoid arthritis, and HIV.

"The growing demand for outsourced clinical studies provided by quality CRO's is tremendous," stated Dr. Sohail Khattak, CEO of Qualia. "There are more than 23,000 potential new drugs being developed and Qualia will be involved in many of those clinical trials."

At the time of the grand opening Qualia had committed contracts for approximately $1.3 million in contracts, and was already processing its first trials.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.


Contact Information